Status:

TERMINATED

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Conditions:

Fallopian Tube Cancer

Ovarian Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemotherapy drugs ma...

Detailed Description

OBJECTIVES: Primary * Determine the maximum tolerated dose of weekly topotecan in patients with progressive or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer and a...

Eligibility Criteria

Inclusion

  • Histological diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer
  • Progressive or recurrent disease
  • Received ≥ 1 prior course of chemotherapy
  • Measurable or evaluable disease OR disease assessable by CA 125, defined as CA 125 \> normal that has increased over 2 readings \> 14 days apart
  • Karnofsky performance status 10-50%
  • Absolute neutrophil count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Creatinine ≤ 1.5 mg/dL
  • Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 times ULN
  • SGOT ≤ 3 times ULN
  • Life expectancy ≥ 12 weeks
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use accepted and effective non-hormonal contraception

Exclusion

  • Other neoplasm within the past 5 years except for nonmetastatic, nonmelanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or chemotherapy
  • Septicemia, severe infection, or acute hepatitis
  • Severe gastrointestinal bleeding, defined as requiring a blood transfusion or hospitalization

Key Trial Info

Start Date :

August 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2006

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT00287859

Start Date

August 1 2004

End Date

December 1 2006

Last Update

November 29 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Minnesota Cancer Center

Minneapolis, Minnesota, United States, 55455

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | DecenTrialz